Crossmark

The risk and economic burden of interstitial lung disease in patients with non-small cell lung cancer treated with immune checkpoint inhibitors and targeted therapies

Crossref DOI link: https://doi.org/10.1186/s12931-026-03871-4

Published Online: 2026-08-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kwon, Swan

Kim, You-Hyang

Byun, Joo-Young

Lee, Eui-Kyung
License Information

Text and Data Mining valid from 2026-08-19

Accepted Manuscript valid from 2026-08-19
More Information

Article History

Received: 3 March 2026

Accepted: 8 August 2026

First Online: 19 August 2026

Declarations

Ethics approval and consent to participate: This study was conducted in accordance with relevant institutional and national ethical guidelines, and was exempt from further ethical review by the Institutional Review Board of Sungkyunkwan University, due to its retrospective use of anonymized secondary data (SKKU IRB 2024-01-053). The requirement for obtaining informed consent was waived by the board.

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below